Elevated plasma EDA fibronectin in primary myelofibrosis is determined by high allele burden of JAK2V617F mutation and strongly predicts splenomegaly progression. [PDF]
Malara A +6 more
europepmc +1 more source
Hematopoietic JAK2V617F mutation-induced reprogramming of blood and bone marrow megakaryocytes. [PDF]
Lu S +5 more
europepmc +1 more source
Validation of the Primerdesign Quantitative Allele Specific Amplification Kit for the Detection of JAK2V617F Mutation. [PDF]
Vaz D, Netshidzivhani T, Potgieter J.
europepmc +1 more source
Decoding Endothelial MPL and JAK2V617F Mutation: Insight Into Cardiovascular Dysfunction in Myeloproliferative Neoplasms. [PDF]
Zhang H +6 more
europepmc +1 more source
Linezolid Acts as a Selective Inhibitor of the JAK2V617F Mutation
A. Gumerova +19 more
semanticscholar +1 more source
Dibenzo [a, c] phenazin-11-yl(phenyl) methanone (SBLJ23), a novel selective inhibitor targeting JAK2<sup>V617F</sup> mutation in myeloproliferative neoplasms. [PDF]
Abohassan M +3 more
europepmc +1 more source
Youwen Qin +3 more
semanticscholar +1 more source
Characterization of JAK2V617F and the JAK2 46/1 germline haplotype in myeloproliferative neoplasms in a Saudi Arabian cohort: a case-based analysis. [PDF]
Mutrib N +8 more
europepmc +1 more source
The <i>JAK2</i> V617F revolution in myeloproliferative neoplasms. [PDF]
Tefferi A.
europepmc +1 more source

